Three patients with advanced cutaneous angiosarcoma treated with eribulin: investigation of serum soluble CD163 and chemokine (C-X-C motif) ligand 10 as possible biomarkers predicting the biological behaviour of angiosarcoma.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 29663331.
- Also identified by DOI 10.1111/bjd.16676.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cutaneous angiosarcoma (CAS) is a highly aggressive vascular tumour that recurs locally and metastasizes early. Although chemoradiotherapy with taxanes shows a high response rate with prolonged survival, second-line therapy for advanced CAS remains contentious. This report describes three patients with advanced CAS treated with eribulin. In addition, we investigated serum soluble (s)CD163, chemokine (C-X-C motif) ligand 10 (CXCL10) and chemokine (C-C motif) ligand 2 levels at several time points of tumour progression in these patients, revealing serum levels of sCD163 and CXCL10 as potential biomarkers for progression of CAS.
Medical subject headings
- Antigens, CD
- Antigens, Differentiation, Myelomonocytic
- Biomarkers, Tumor
- Chemokine CXCL10
- Furans
- Hemangiosarcoma
- Ketones
- Receptors, Cell Surface
- Skin Neoplasms